Carcinoma of the Tongue

Anatomy (relevant to spread)

The oral tongue (anterior two-thirds) is separated from the base of tongue by the circumvallate papillae. Lateral border lymphatics drain ipsilaterally, while the tip, midline, and base drain bilaterally - explaining why midline/ventral lesions carry a higher risk of bilateral neck metastasis. Motor supply is via the hypoglossal nerve, sensation via the lingual nerve, and taste via the facial nerve (chorda tympani) (Scott-Brown's Otorhinolaryngology, p. 226).

Etiology / Risk Factors

Tobacco (smoked or chewed) and alcohol - up to 70% of patients report significant use of both, and they act synergistically.
Betel nut/chewing tobacco - major factor in populations where oral cancer (rather than tongue-specific) predominates.
HPV infection - an established and rising cause, more classically linked to base-of-tongue/oropharyngeal cancer, less commonly the oral tongue.
Immunosuppression and possibly poor oral hygiene.
Premalignant lesions: leukoplakia (white patch, malignant transformation risk ~1-3%/year at some sites) and erythroplakia (red, inflammatory lesion) - erythroplakia is actually the most common presentation of early squamous cell carcinoma of the tongue.
Age/sex: most patients are over 40 (90%), peak incidence in the 6th-8th decade, slightly more common in males, though the male:female ratio is narrowing due to rising alcohol use in women.
A distinct subgroup of young patients without classic risk factors exists, with incidence rising from 4% (1971) to 18% (1993) in the US, suggesting an underlying genetic susceptibility to carcinogenesis in this cohort.

(K J Lee's Essential Otolaryngology, p. 847; Scott-Brown's Otorhinolaryngology Head & Neck Surgery, p. 226)

Pathology

Over 90% are squamous cell carcinoma (SCC), arising most often on the lateral border and middle third of the tongue (only 4-5% occur on the dorsum). Gross patterns are exophytic, ulcerative, or infiltrative - the ulcerative and infiltrative types predominate on the tongue. Histologically, most tumors are well to moderately differentiated. Invasive SCC shows keratin deposits, squamous cell nests, and stromal fibrosis, with basaloid, papillary, spindle-cell, and verrucous subtypes also described. Depth of invasion >2-4 mm and perineural invasion correlate strongly with regional metastasis, recurrence, and mortality.

Clinical Features

Early disease: may be asymptomatic or present as an erythroplakic patch; lesions <1 cm may only be found on routine exam.
Symptomatic disease: an indurated, ulcerated area is the most common finding; pain, a lump, or non-healing ulcer are typical complaints. Despite oral tongue lesions being more symptomatic than base-of-tongue lesions, patients often delay 4-6 months before seeking care.
Base-of-tongue tumors are often clinically silent until deep infiltration occurs, tend to be less differentiated, and frequently present at a later stage (III/IV) with nodal metastasis already established, compared with oral tongue cancers which usually present at stage I/II.
Late features: tongue fixation, decreased tongue sensation/numbness, dysarthria, dysphagia/odynophagia, referred otalgia, hoarseness, hemoptysis, weight loss, and a palpable neck mass.
Nodal disease: clinically palpable cervical lymphadenopathy at presentation occurs in ~21-34% of patients; occult (subclinical) metastasis has been found in up to 53%, related to tumor thickness. Levels I-III are the primary nodal drainage basins. Up to 4.5% may have occult contralateral disease.

Diagnosis / Workup

History: tobacco/alcohol use, pain, weight loss, dysphagia/odynophagia, referred otalgia, hemoptysis, neck mass, hoarseness, speech difficulty.
Examination: complete head and neck exam with bimanual palpation of the tumor to assess size, site, and infiltration/fixation; careful bilateral neck palpation.
Biopsy: most lesions are amenable to office biopsy for tissue diagnosis; biopsies should include the deep margin and peripheral mucosa, since deep sampling helps estimate tumor thickness and invasive-front grading (which informs metastatic risk).
Imaging: CT/MRI of the primary and neck (though sensitivity for detecting cervical nodal disease is only moderate); intraoral or resected-specimen ultrasonography can accurately assess tumor thickness, which guides neck management. PET-CT is used for staging in more advanced disease and metastasis workup.
Staging: AJCC TNM system, incorporating depth of invasion for T-staging of oral cavity cancers.

Treatment

Management is primarily surgical, with radiation and chemotherapy playing key roles in advanced disease, poor surgical candidates, or as adjuvant therapy.

Early-stage (T1-T2): Partial glossectomy with reconstruction (primary closure, healing by secondary intention, or skin graft) is preferred; single-modality therapy (surgery or radiation, including brachytherapy) is generally sufficient. Surgery is usually favored upfront over radiation when long-term morbidity, cost, and other factors are weighed.
Neck management: Elective neck dissection (commonly levels I-III, "supraomohyoid") is considered given the high rate of occult metastasis, especially when tumor depth exceeds threshold values (commonly cited around 2-4 mm); bilateral treatment is considered for midline/ventral or base-of-tongue lesions.
Advanced/extensive local disease (T3-T4): Near-total or total glossectomy may be required. Bone (mandibular) invasion generally mandates surgical resection (composite resection) rather than chemoradiation alone. Flap reconstruction (e.g., free tissue transfer) is used to restore form and function; even so, glossectomy carries significant morbidity (swallowing and airway problems), and laryngectomy is occasionally needed for chronic aspiration. In select cases total glossectomy can be performed while preserving the larynx.
Chemoradiation: Considered for T4 disease or when surgery is not feasible; also used as an adjuvant after surgery for adverse features (positive margins, perineural/lymphovascular invasion, extranodal extension, multiple nodal metastases).
Rehabilitation: Speech and swallowing rehabilitation is an integral part of post-treatment care given the functional impact of resection and radiation.
Prognosis: Recurrent disease, mandibular invasion, and lymph node involvement all carry a poor prognosis.

(K J Lee's Essential Otolaryngology, pp. 847-849; Scott-Brown's Otorhinolaryngology Head & Neck Surgery, pp. 225-227)

Recent Evidence (may refine/update the above)

A few recent systematic reviews are relevant and worth flagging since they postdate standard textbook coverage:

Postoperative radiotherapy in early-stage tongue carcinoma - a 2025 systematic review/meta-analysis (PMID: 39672329) examines whether adjuvant RT benefits early-stage (T1-T2) tongue cancer, which could refine the "surgery alone is sufficient" guidance above for select high-risk early lesions.
Reconstruction algorithms for tongue malignancy defects - a 2025 systematic review (PMID: 40503748) proposes a treatment algorithm for free-flap reconstruction after glossectomy.
Targeted therapy for oral potentially malignant disorders - a 2025 systematic

Give answers

Carcinoma of the Tongue

Anatomy (relevant to spread)

Etiology / Risk Factors

Tobacco (smoked or chewed) and alcohol - up to 70% of patients report significant use of both, acting synergistically.
Betel nut/chewing tobacco - major factor in populations where oral cancer predominates.
HPV infection - established and rising, more classically linked to base-of-tongue/oropharyngeal cancer, less commonly the oral tongue.
Immunosuppression and possibly poor oral hygiene.
Premalignant lesions: leukoplakia (white patch, malignant transformation ~1-3%/year at some sites) and erythroplakia (red, inflammatory lesion) - erythroplakia is the most common presentation of early SCC of the tongue.
Age/sex: 90% of patients are over 40, peak incidence 6th-8th decade, slightly more common in males, though the ratio is narrowing due to rising alcohol use in women.
A distinct subgroup of young patients without classic risk factors exists (incidence rose from 4% in 1971 to 18% in 1993 in the US), suggesting an underlying genetic susceptibility to carcinogenesis in this group.
K J Lee's Essential Otolaryngology, p. 847; Scott-Brown's Otorhinolaryngology Head & Neck Surgery, p. 226

Pathology

Over 90% are squamous cell carcinoma (SCC), arising most often on the lateral border and middle third of the tongue (only 4-5% occur on the dorsum). Gross patterns are exophytic, ulcerative, or infiltrative - ulcerative and infiltrative types predominate. Most tumors are well to moderately differentiated. Invasive SCC shows keratin deposits, squamous cell nests, and stromal fibrosis, with basaloid, papillary, spindle-cell, and verrucous subtypes also seen. Depth of invasion >2-4 mm and perineural invasion correlate strongly with regional metastasis, recurrence, and mortality.

Clinical Features

Early disease: may be asymptomatic or present as an erythroplakic patch; lesions <1 cm may be found only on routine exam.
Symptomatic disease: an indurated, ulcerated area is the most common finding; pain, a lump, or non-healing ulcer are typical complaints. Patients often delay 4-6 months before seeking care.
Base-of-tongue tumors are often clinically silent until deep infiltration occurs, tend to be less differentiated, and present later (stage III/IV with nodal disease), versus oral tongue cancers which usually present at stage I/II.
Late features: tongue fixation, decreased tongue sensation/numbness, dysarthria, dysphagia/odynophagia, referred otalgia, hoarseness, hemoptysis, weight loss, and a palpable neck mass.
Nodal disease: clinically palpable cervical lymphadenopathy at presentation in ~21-34%; occult (subclinical) metastasis found in up to 53%, related to tumor thickness. Levels I-III are the primary drainage basins. Up to 4.5% may have occult contralateral disease.

Diagnosis / Workup

History: tobacco/alcohol use, pain, weight loss, dysphagia/odynophagia, referred otalgia, hemoptysis, neck mass, hoarseness, speech difficulty.
Examination: complete head and neck exam with bimanual palpation of the tumor to assess size, site, and infiltration/fixation; bilateral neck palpation.
Biopsy: most lesions are amenable to office biopsy; biopsy should include the deep margin and peripheral mucosa, since deep sampling helps estimate tumor thickness and invasive-front grading (informs metastatic risk).
Imaging: CT/MRI of the primary and neck (moderate sensitivity for nodal disease); intraoral or resected-specimen ultrasound assesses tumor thickness to guide neck management. PET-CT for staging advanced disease/distant metastasis.
Staging: AJCC TNM system, incorporating depth of invasion for T-staging of oral cavity cancers.

Treatment

Management is primarily surgical, with radiation and chemotherapy for advanced disease, poor surgical candidates, or as adjuvant therapy.

Early-stage (T1-T2): Partial glossectomy with reconstruction (primary closure, secondary intention, or skin graft); single-modality therapy (surgery or radiation, including brachytherapy) is usually sufficient. Surgery is favored upfront over radiation when long-term morbidity and cost are weighed.
Neck management: Elective neck dissection (typically levels I-III) given the high rate of occult metastasis, especially with tumor depth beyond threshold values (commonly cited 2-4 mm); bilateral treatment considered for midline/ventral or base-of-tongue lesions.
Advanced/extensive local disease (T3-T4): Near-total or total glossectomy may be required. Mandibular bone invasion generally mandates surgical (composite) resection rather than chemoradiation alone. Flap reconstruction (free tissue transfer) restores form and function; glossectomy still carries significant morbidity (swallowing, airway problems), and laryngectomy is occasionally needed for chronic aspiration. In select cases total glossectomy is done while preserving the larynx.
Chemoradiation: For T4 disease or when surgery is not feasible; also used adjuvantly after surgery for adverse features (positive margins, perineural/lymphovascular invasion, extranodal extension, multiple nodal metastases).
Rehabilitation: Speech and swallowing rehabilitation is integral given the functional impact of resection/radiation.
Prognosis: Recurrent disease, mandibular invasion, and lymph node involvement carry a poor prognosis.
K J Lee's Essential Otolaryngology, pp. 847-849; Scott-Brown's Otorhinolaryngology Head & Neck Surgery, pp. 225-227

Recent Evidence Worth Noting

A few recent systematic reviews refine points above:

Postoperative radiotherapy in early-stage tongue carcinoma - a 2025 systematic review/meta-analysis (PMID: 39672329) evaluates whether adjuvant RT benefits early-stage (T1-T2) disease, which can modify the "surgery alone suffices" guidance for select high-risk early lesions (e.g., adverse depth of invasion or perineural invasion).
Reconstruction algorithms for tongue malignancy defects - a 2025 systematic review (PMID: 40503748) proposes a structured free-flap reconstruction algorithm after glossectomy, useful for planning advanced-stage surgical reconstruction.
Targeted therapy for oral potentially malignant disorders - a 2025 systematic review (PMID: 40051114) looks at agents like cetuximab, nivolumab, erlotinib, celecoxib, and metformin for premalignant lesions (leukoplakia/erythroplakia), relevant to future chemoprevention strategies rather than established standard-of-care today.

These do not overturn the core surgery-first paradigm but suggest evolving refinement in adjuvant RT selection criteria and reconstructive planning - worth discussing with a head and neck oncology team when individualizing treatment.

This is a shared conversation. Sign in to Orris to start your own chat.